AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 287: H268-H276, 2004. First published February 26, 2004; doi:10.1152/ajpheart.00007.2004
0363-6135/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/H268    most recent
00007.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, A. N.
Right arrow Articles by Peters, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, A. N.
Right arrow Articles by Peters, K. G.

Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease

Andrew N. Carr, Michael G. Davis, Elaine Eby-Wilkens, Brian W. Howard, Bryan A. Towne, Thomas E. Dufresne, and Kevin G. Peters

Cardiovascular Research Division, Health Care Research Center, Procter and Gamble Pharmaceuticals, Mason, Ohio 45040

Submitted 6 January 2004 ; accepted in final form 24 February 2004


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
During embryonic development, the growth of blood vessels requires the coordinated activation of endothelial receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptor-2 (VEGFR-2) and Tie-2. Similarly, in adulthood, activation of endothelial RTKs has been shown to enhance development of the collateral circulation and improve blood flow to ischemic tissues. Recent evidence suggests that RTK activation is negatively regulated by protein tyrosine phosphatases (PTPs). In this study, we used the nonselective PTP inhibitor bis(maltolato)oxovanadium IV (BMOV) to test the potential efficacy of PTP inhibition as a means to enhance endothelial RTK activation and improve collateral blood flow. In cultured endothelial cells, pretreatment with BMOV augmented VEGFR-2 and Tie-2 tyrosine phosphorylation and enhanced VEGF- and angiopoietin-1-mediated cell survival. In rat aortic ring explants, BMOV enhanced vessel sprouting, a process that can be influenced by both VEGFR-2 and Tie-2 activation. Moreover, 2 wk of BMOV treatment in a rat model of peripheral vascular disease enhanced collateral blood flow similarly to VEGF, and after 4 wk, BMOV was superior to VEGF. Taken together, these studies provide evidence that PTPs are important regulators of endothelial RTK activation and for the first time demonstrate the potential utility of phosphatase inhibition as a means to promote collateral development and enhance collateral blood flow to ischemic tissue.

inhibitor; protein; coronary artery; Tie-2; vascular endothelial growth factor receptor

BLOOD VESSEL GROWTH AND DEVELOPMENT are prerequisites for adequate tissue perfusion, and disturbances in blood flow can result in ischemia and tissue damage. In the case of atherosclerotic cardiovascular disease and other more rare vascular disorders, occlusive lesions formed in arteries that are critical for the maintenance of blood supply to the heart, brain, kidneys, and extremities can result in substantial tissue damage or loss of function. In coronary artery disease (CAD), flow-limiting lesions can result in angina or, in severe cases, myocardial infarction. In the case of peripheral vascular disease (PVD), lesions in the vessels that supply the legs can lead to intermittent claudication and ischemic ulcers, which can deteriorate so as to require limb amputation. The importance of treating PVD is underscored by its association with increased risk of atherosclerotic events such as stroke and myocardial infarction (1). The increasing prevalence of PVD in Europe and North America, estimated at ~27 million people and 16% of the population over age 55, indicates that PVD represents a clearly unmet medical need (50).

Presently, approaches to treat occlusive cardiovascular disorders include interventional or surgical procedures to reestablish the circulation to the occluded artery (34). However, some patients with occluded arteries are asymptomatic due to the development or enlargement of collateral vessels that maintain blood flow distal to the site of occlusion (38). Nevertheless, in most patients with atherosclerosis, the collateral circulation remains insufficient for complete abrogation of symptoms or protection from ischemic tissue damage, prompting the search for novel therapeutic approaches to enhance collateral development.

The process of blood vessel development is orchestrated by angiogenic polypeptide growth factors that act via a family of conserved endothelial receptor tyrosine kinases (RTKs; Refs. 6, 12). For example, vascular endothelial growth factor receptor-2 (VEGFR-2) and Tie-2, the receptors for VEGF and the angiopoietins, respectively, are expressed principally in endothelial cells, and disruption of their function results in embryonic lethality due to distinct vascular defects. Although these receptors exhibit unique biological activity, their signaling is initiated by a common mechanism (20, 39). Growth factor binding results in receptor dimerization/oligomerization, activation of the intracellular kinase domain, and autophosphorylation of the receptor on specific tyrosine residues. Receptor phosphorylation serves a dual purpose, first to further increase tyrosine kinase activity, and second, to create binding sites for the recruitment of signaling molecules with phosphotyrosine binding motifs. These interactions lead to amplification of downstream effectors including activation of other protein kinases (e.g., mitogen-activated protein kinases, Akt), which converge to promote endothelial cell migration, proliferation, and survival, all of which are important events in blood vessel assembly.

Demonstrating the therapeutic potential of activating endothelial RTKs for the treatment of atherosclerotic cardiovascular disease, delivery of polypeptide growth factors in animal models, including fibroblast growth factor (FGF), VEGF, and angiopoietin-1 (Ang-1) results in improved collateral blood flow (4, 26, 42, 44, 49, 56). However, because polypeptide growth factors are expensive to produce and difficult to administer, their use as therapeutic agents is currently limited. In addition, like the development of the embryonic vasculature, optimal collateral development in vivo may require the coordinated activation of multiple RTKs and necessitate the delivery of multiple growth factors (4, 15, 37). Thus there has been growing interest in developing alternative approaches to activating endothelial RTKs for treatment of occlusive atherosclerotic cardiovascular disease.

An emerging alternative approach to enhancing RTK activation is to block the action of protein tyrosine phosphatases (PTPs) that counteract RTK activity (33, 57). Indeed, the tyrosine phosphatase PTP-1B negatively regulates insulin signaling by dephosphorylating the insulin RTK, and mice lacking PTP-1B exhibit enhanced insulin-mediated insulin receptor autophosphorylation, which results in enhanced insulin sensitivity (7, 25). As a proof of concept that PTP-1B inhibition could improve insulin signaling, vanadium compounds such as the potent but nonselective tyrosine phosphatase inhibitors sodium orthovanadate (NaVO4) and bis(maltolato)oxovanadium IV (BMOV) have been shown to augment insulin receptor activation and insulin action in diabetic rats (36, 47).

On the basis of these studies, we hypothesized that as with the insulin receptor, the actions of RTKs that promote angiogenesis and collateral development could be limited by PTP activity. Although most investigators use pan-tyrosine phosphatase inhibitors in cell lysis buffers to maintain RTK phosphorylation status, the concept of inhibition of PTPs to increase RTK signaling for promoting collateral blood flow is presently unsupported. To test this hypothesis, the organovanadium phosphatase inhibitor BMOV was used to demonstrate that inhibition of endothelial PTP activity enhanced the activation of endothelial RTKs, leading to augmentation of cellular responses important for angiogenesis and enhanced angiogenesis in the aortic ring explant assay. Consistent with these studies, BMOV also augmented collateral blood flow in a rat model of PVD. These data support the hypothesis that PTPs regulate endothelial RTK activation and provide the first demonstration of PTP inhibition as a novel approach for the treatment of occlusive atherosclerotic cardiovascular disease.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animal experiments. All animal work was conducted in accordance with institutional animal care and use guidelines.

Cell culture and receptor activation assays. Human umbilical vein endothelial cells (HUVECs; Clonetics) were grown to 90% confluence on 100-mm dishes. Cells were preincubated with BMOV at various concentrations as described in the text and then stimulated with either recombinant Ang-1 or recombinant VEGF165 (165-amino acid isoform of VEGF; R&D Systems) for 7 or 5 min, respectively. After stimulation, the cells were lysed in Triton lysis buffer (TLB: 20 mmol/l Tris·HCl, pH 8.0, 137 mmol/l NaCl, 10% glycerol, 1% Triton X-100, 2 mmol/l EDTA, 1 mM sodium orthovanadate, 1 mmol/l sodium fluoride, 1 mmol/l PMSF, 1 µg/ml leupeptin, and 1 µg/ml pepstatin) at 4°C. Cell lysates stimulated with Ang-1 were immunoprecipitated using 2 µg of anti-Tie-2 antibody (19) and 25 µl of protein A/G Plus. Lysates stimulated with VEGF165 were immunoprecipitated with 25 µl of wheat germ agglutinin (lectin from Triticum vulgaris). After overnight incubation, the complexes were centrifuged, washed once in TLB, and eluted by boiling in 30 µl of 1x sample buffer (50 mmol/l Tris·HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1 mol/l DTT, and 0.1% bromphenol blue). Each sample (20 µl) was loaded onto a 6% SDS-PAGE gel, transferred to PVDF, and phosphotyrosine Western blotting was performed using anti-phosphotyrosine antibody PY-99. After exposure, the blots were stripped and reprobed with the anti-Tie-2 receptor Ab33 or anti-VEGFR-2 (51). The resulting films were scanned and quantitated using Quantity One software.

Cell survival assay. HUVECs were plated in 96-well tissue culture plates (20,000 cells/well) and serum starved in DMEM with 0.2% BSA. After 2 h, cells were treated with DMEM/0.2% BSA and growth factor and/or BMOV for 72 h. Changes in luminescence were measured using a Victor V plate reader.

Rat aortic ring assay of angiogenesis. The isolated rat aortic ring model of angiogenesis was performed based on previously described studies (31). Male Sprague-Dawley rats (150–175 g; Charles River) were anesthetized with Nembutal (50 mg/kg body wt ip) injection. The thoracic aorta was excised and transferred to endothelial basal media (EBM; Clonetics) that contained 1% antibiotics-antimycotic. Aortas were cross-sectioned at ~1-mm intervals, and the resulting tissues were placed in a 24-well tissue-culture plate. Vessels were overlaid with 450 µl of collagen solution that consisted of 8 volumes of 3 mg/ml rat-tail collagen (Sigma) in 0.1% acetic acid, 1 volume of 10x medium 199 (phenol red free) supplemented with 100 mg/l L-glutamine, and 1 volume of 10x collagen buffer (0.05 N NaOH, 200 mmol/l HEPES, 260 mmol/l NaHCO3). The collagen solution was allowed to solidify for 1 h and was covered with 1 ml of EBM with or without BMOV. Images (TIFF) were taken using a SPOT camera connected to a Nikon inverted microscope, and vessel growth was quantitated using automated image-analysis software.

In vivo Tie-2 receptor phosphorylation. Fasted rats (body wt, 250–300 g) were infused with either saline or BMOV (1.73 mg/100 g of body wt) for 5 min, which was followed immediately by a 2-min infusion with either saline or Ang-1 (5 µg/100 g of body wt) via a carotid artery catheter (a polypropylene glycol-coated cannula was inserted 2.5 cm into the left carotid such that compounds were delivered into the aortic arch/descending aorta). Eight minutes after the dosing, the animals were euthanized and lung tissue was harvested using a 6-mm disposable punch biopsy. Samples were flash-frozen in liquid nitrogen and stored at –80°C until assayed. Frozen tissue (250 mg) was homogenized in RIPA buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% SDS, 1 mM sodium orthovanadate, 1 mM NaF, 10 nM okadaic acid, and 1 complete protease inhibitor tablet (Roche)]. Homogenates were centrifuged at ~21,000 g for 30 min at 4°C. Supernatants were recovered, and protein concentrations were determined by bicinchoninic acid assay (Pierce). Extracted protein (1 mg) was precleared with 25 µl of protein A/G-Plus agarose beads (Santa Cruz Biotechnology) for 1 h at 4°C. The Tie-2 receptor was immunoprecipitated as described above.

Femoral artery ligation and blood flow measurements. Male Sprague-Dawley rats (body wt, 325–350 g; Taconic) were used in this study. The basic design of this model consisted of an initial sterile surgery at which time both femoral arteries were ligated (distal to the inguinal ligament and proximal to the femoral circumflex), and in the case of the VEGF groups, an osmotic pump was implanted for continuous delivery of the VEGF (15 µg·kg–1·day–1) through the jugular vein to allow systemic perfusion of the peptide (53). Dosing for the other treatment groups consisted of subcutaneous injections every 4 days beginning immediately after the surgery and continuing for up to 4 wk with either BMOV (dose, 0.8 mg/100 g of tissue; injection volume, 3.6 ml/kg) or vehicle (injection volume, 3.6 ml/kg). At the end of the treatment period, animals were instrumented (catheters were inserted into a carotid and caudal artery) for blood flow measurements using 0.5 ml of 15-µm fluorescent microspheres (Molecular Probes FluoroSpheres; orange and yellow-green; 5 x 105 microspheres) and subjected to exercise challenges (25 m/min at a 7° incline) on the treadmill to assess peak collateral flow. Tissues were digested with 4 N KOH overnight and processed (vacuum-filter extracted). Fluorescence in the supernatant was measured using a luminescence spectrometer (LS50B; PerkinElmer) at wavelengths of 352 and 506 nm for orange and yellow-green microspheres, respectively. Raw data were converted to blood flow (in ml·min–1·100 g of tissue–1) by the equation {[tissue fluorescence/tissue weight (in g)]/[reference blood fluorescence/blood withdraw rate (in ml/min)]} x 100 g. "Acute" animals were ligated on the same day as the exercise challenge. Animals in the 4-wk treatment groups for BMOV and vehicle were given injections on days 0, 4, 8, 12, 16, 20, and 24; in the 2-wk treatments, injections were given on days 0, 4, 8, and 12. VEGF165 was delivered continuously for either 2 or 4 wk. Flow values for left- and right-leg tissues were averaged together to create one value for each animal as long as even distribution was exhibited between the kidneys.

Statistical analysis. Values represent means ± SE. Statistical comparisons were made with Student's t-test and one- or two-way ANOVA (Tukey) where indicated with significance imparted at P values <0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
BMOV promotes endothelial RTK activation and enhances endothelial cell survival. To test the role of PTPs in the regulation of endothelial RTK activation, the phosphorylation status of Tie-2 and VEGFR-2 was examined in HUVECs in response to BMOV. In the absence of exogenous growth factors, Tie-2 and VEGFR-2 receptor phosphorylation was minimal (Fig. 1). As expected, increasing concentrations of Ang-1 or VEGF165 in the growth media resulted in a corresponding increase in Tie-2 or VEGFR-2 receptor tyrosine phosphorylation, respectively. Pretreatment of HUVECs with 50 or 100 µmol/l BMOV for 30 min increased Tie-2 receptor phosphorylation at baseline and augmented Ang-1-mediated phosphorylation in a concentration-dependent manner (Fig. 1A). Similar results were obtained for VEGFR-2 in response to increasing concentrations of VEGF (Fig. 1B).



View larger version (45K):
[in this window]
[in a new window]
  		Fig. 1. Bis(maltolato)oxovanadium IV (BMOV) enhances activation of endothelial receptor tyrosine kinases (RTKs). Human umbilical vein endothelial cells (HUVECs) were stimulated with increasing concentrations of angiopoietin-1 (Ang-1) for 7 min or the 165-amino acid isoform of vascular endothelial growth factor (VEGF165) for 5 min after a 30-min incubation with either vehicle (open bars) or 50 µmol/l (solid bars) or 100 µmol/l (gray bars) of BMOV. Tie-2 receptors were immunoprecipitated (IP) using a Tie-2-specific antibody (A); wheat germ agglutinin (WGA) was used for VEGF receptor-2 (VEGFR-2) receptors (B). Western blots were probed with a tyrosine phosphorylation-specific antibody ({alpha}P-Tyr), stripped, and reprobed with a Tie-2 ({alpha}Tie-2)- or VEGFR-2 ({alpha}VEGFR-2)-specific antibody (top). Quantitation of Tie-2 or VEGFR-2 phosphorylation is expressed as the ratio of phosphotyrosine signal to total receptor levels (bottom). Data shown are from 1 of 3 experiments with similar results.

 
One mechanism by which activation of RTKs promotes angiogenesis is via their antiapoptotic/prosurvival effects in endothelial cells (13, 22, 24, 35). To determine whether the increases in VEGFR-2/Tie-2 receptor activation through BMOV had functional consequences, we examined cell survival in HUVECs. In this assay, cell survival was quantitated by serum starving HUVECs for 72 h (with or without growth factors) and measuring ATP as a surrogate marker of cell metabolism. As expected, both Ang-1 and VEGF165 resulted in increased cell survival compared with control (Fig. 2). Consistent with the receptor activation data, BMOV significantly enhanced cell survival in the absence or presence of either growth factor, which demonstrates that phosphatase inhibition can facilitate critical cellular responses downstream of endothelial RTK activation.



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 2. BMOV promotes cell survival downstream of endothelial RTKs. Cell survival was measured by quantitating luminescence (in RLU), which reflects the total amount of ATP remaining after 72 h in culture. Ang-1 (A) and VEGF (B) promoted cell survival in a concentration-dependent manner (open bars), and this effect was enhanced in the presence of 5 µmol/l (solid bars) and 50 µmol/l (gray bars) BMOV. *P < 0.05 vs. untreated cells; {dagger}P < 0.05 vs. VEGF or Ang-1 alone and VEGF or Ang-1 with 5 µmol/l BMOV-treated cells; two-way ANOVA, Tukey's post hoc test.

 
BMOV enhances angiogenesis in aortic ring explants. The ability of BMOV to enhance VEGFR-2 and Tie-2 receptor activation and cell survival suggested that PTP inhibition should also promote blood vessel growth. To test this possibility, we utilized the rat aortic ring model, which is a well-accepted model of angiogenesis (32). In this assay, vessels arise spontaneously from sections of thoracic aorta cultured under serum-free conditions in a collagen matrix. Vessel growth in this model can be increased in the presence of VEGF165 or Ang-1, which suggests a role for both VEGFR-2 and Tie-2 in this model (31, 60). Furthermore, in our system, we verified that these vascular sprouts are endothelial in nature using immunohistochemical staining with von Willebrand factor or Tie-2-specific antibodies and that these vessels form a lumen, confirmed by electron microscopy (data not shown), as previous authors have described (32). Vessel sprouting, measured as the total vessel area (area) and average vessel length (extent), was significantly enhanced in the presence of BMOV after 7 days in culture (Fig. 3), whereas at the highest concentration, BMOV inhibited vessel formation. These findings suggest that inhibiting PTPs may have beneficial effects on blood vessel growth, but that global PTP inhibition using BMOV may be limited by its nonspecific nature. Alternatively, because BMOV enhanced endothelial cell survival at similar concentrations, the inhibition of vessel growth by BMOV may be due to the effects of BMOV on other cell types or on other endothelial responses required for vessel formation in this model. In any case, these data demonstrate that PTP inhibition can augment innate mechanisms of blood vessel growth and remodeling in a complex multicellular system involving activation of multiple endothelial RTKs.



View larger version (41K):
[in this window]
[in a new window]
  		Fig. 3. BMOV enhances angiogenesis in rat aortic ring model. Rat aortic rings were cultured for 7 days in endothelial basal media alone or with increasing concentrations of BMOV. Spontaneous growth of new vessels was significantly increased by inclusion of BMOV in the media in a concentration-dependent manner. Images of control and 6.6 µmol/l BMOV-treated aortic rings at day 7 (top). Images are at x20 magnification. Angiogenesis was quantitated by measuring the total vessel area and the average length of vessels (extent) extending from the original vessel (bottom). Vessel growth was quantitated using automated imaging software developed in-house. Data are from n = 10 rings for controls and n = 5 rings for all other groups. *P < 0.05 vs. control, one-way ANOVA.

 
BMOV enhances Tie-2 receptor activation in vivo. Although BMOV exhibited a proangiogenic profile in isolated cells and organ culture, it was unclear whether BMOV could recapitulate these properties in vivo. To elucidate whether tyrosine phosphatase inhibition could modulate endothelial RTK activity in an animal, we developed an in vivo receptor activation assay. In this assay, saline, Ang-1 (5 µg/100 g of body wt), BMOV (1.73 mg/100 g of body wt), or the combination of Ang-1 and BMOV were administered intra-arterially via the carotid artery. Because Tie-2 expression is relatively high in the lung (52), we harvested lung tissue from treated animals for the analysis of receptor activation. Infusion of Ang-1 resulted in an increase in Tie-2 phosphorylation in the lungs (Fig. 4), which demonstrates that the receptor can be activated in vivo. Administration of BMOV alone slightly increased Tie-2 phosphorylation but did not increase phosphorylation to the same extent as Ang-1. However, BMOV augmented Ang-1-mediated Tie-2 phosphorylation, which demonstrates that BMOV could access vascular endothelium and that PTPs limit Ang-1-mediated Tie-2 activation in vivo.



View larger version (32K):
[in this window]
[in a new window]
  		Fig. 4. BMOV enhances activation of Tie-2 receptor in vivo. Animals were given intravenous infusion of either saline (A), 5 µg/100 g of body wt Ang-1 (B), 1.73 mg/100 g of body wt BMOV (C), or BMOV and Ang-1 (D). Western blots (top) were probed sequentially for phosphotyrosine ({alpha} P-Tyr) and Tie-2 ({alpha} Tie-2) and quantitated (bottom). Data are representative of single animals at each treatment performed in duplicate.

 
Phosphatase inhibition with BMOV enhances collateral blood flow in vivo. Taken together, the preceding studies indicated that PTP inhibition could enhance the activation, cellular responses, and angiogenic actions of endothelial RTKs in vitro and in vivo. On the basis of these data, we tested the ability of BMOV to augment collateral development in a rat model of PVD. The rat hindlimb model of arterial insufficiency has been extensively used to study collateral development and is an ideal model to test the effects of BMOV (53). Importantly, previous studies have demonstrated that both exogenous Ang-1 and VEGF165 improve blood flow in this model, thereby indicating that this system, like the aortic ring, is responsive to both of these angiogenic growth factors (5, 55, 56).

At 2 wk of treatment, blood flow in saline-injected animals was greater than that of acutely ligated animals (Fig. 5A), which indicates activation of innate mechanisms to restore collateral blood flow in these rats. VEGF165- or BMOV-treated animals exhibited similar increases in blood flow and flow-reserve recovery expressed as a percentage of maximal blood flow in sham-operated animals (177 ± 22 ml·min–1·100 g of tissue–1) to the calf muscle compared with either saline controls or acutely ligated animals (Fig. 5A). The blood flow reported value for sham-operated animals was similar to previous data (54). At 4 wk postsurgery, collateral blood flow in control and VEGF165-treated rats reached a plateau, as values were similar to those obtained at 2 wk (Fig. 5B). However, collateral blood flow in animals treated with BMOV for 4 wk was significantly improved compared with all 2-wk treatments and, surprisingly, exhibited a greater improvement in blood flow than VEGF165-treated animals for 4 wk. Furthermore, BMOV-treated rats recovered 55% of the maximal blood flow than sham-operated rats compared with 45 and 36% in VEGF and saline-treated rats, respectively. The augmented blood flow in the treatment groups occurred independently of calf weight normalized to body weight or alteration in heart rate (data not shown). Interestingly, improved blood flow in BMOV-treated rats occurred despite a modest decrease in peripheral blood pressure under resting (vehicle: 143 ± 3 mmHg, n = 6; VEGF: 135 ± 5 mmHg, n = 5; not significant vs. vehicle; BMOV: 130 ± 2 mmHg, n = 6; P < 0.05 vs. vehicle) or exercise conditions (vehicle: 148 ± 4 mmHg, n = 6; VEGF: 148 ± 6 mmHg, n = 5; not significant vs. vehicle; BMOV: 130 ± 4 mmHg, n = 6; P < 0.05 vs. vehicle or VEGF). Taken together with the findings in the aortic ring model, these results suggest that PTP inhibition can enhance the innate mechanisms of collateral vessel growth and development.



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 5. BMOV treatment improves maximal collateral blood flow. Collateral blood flow was determined during treadmill exercise (25 m/min) in rats preceded by bilateral femoral artery ligation. One set of animals was ligated just hours before exercising (acute; n = 6) and is compared with saline (n = 6), VEGF165 (15 µg·kg–1·day–1; n = 5), and BMOV (0.8 mg/100 g of body wt; n = 6) -treated rats 2 wk (A) and 4 wk (B) postligation. Blood flow was measured using fluorescent microspheres [reported in ml·min–1·100 g of body tissue–1 (left axis)]. Amount of blood flow recovery with treatment (right axis) is expressed as a percent of the maximal blood flow in sham-operated rats. *P < 0.05 vs. saline at same time point; {dagger}P < 0.05 vs. VEGF at 4 wk; {ddagger}P < 0.05 vs. VEGF and BMOV at 2 wk. Significance determined by one-way ANOVA.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
One emerging approach for the treatment of occlusive cardiovascular disease is to enhance the development and/or remodeling of the collateral circulation by the delivery of proangiogenic polypeptide growth factors such as VEGF, FGF, platelet-derived growth factor, and the angiopoietins. The present study represents the first evidence that an alternative approach, inhibition of endothelial PTP activity, can enhance the biological function of these peptides and most importantly, increase collateral blood flow in an animal model of PVD. The efficacy of BMOV in this model indicates that PTPs limit proangiogenic signals in vivo and that inhibiting endothelial phosphatase activity can shift the balance in favor of endothelial RTK activation and enhance the innate signaling cues to remodel the vasculature and thereby augment collateral blood flow.

Mechanisms of blood flow enhancement by BMOV. Activation of endothelial RTKs such as VEGFR-2 and Tie-2 has been implicated in blood vessel development and growth (6, 12), and their respective ligands have been shown to augment collateral development in animal models of occlusive cardiovascular disease (15, 26, 42, 44, 49, 56). Supporting a role for endothelial phosphatases as negative regulators of endothelial RTK activation, BMOV enhanced activation of VEGFR-2 and Tie-2 in cultured endothelial cells. Additionally supporting this contention, BMOV also enhanced VEGF- and Ang-1-mediated endothelial cell survival, thereby demonstrating that augmentation of receptor activation translates into an enhanced biological response. Moreover, BMOV increased angiogenesis in the rat aortic ring, which indicates that phosphatase inhibition can enhance blood vessel growth and remodeling in a complex multicellular system.

Consistent with the in vitro studies, BMOV augmented Tie-2 activation in vivo and enhanced maximal collateral blood flow in a rat model of PVD. Surprisingly, after 4 wk of treatment, BMOV increased collateral blood flow beyond that observed with VEGF. The increase in blood flow in the treated groups was not due to differential regulation of vascular tone, because measurements were made during strenuous exercise to ensure maximal vasodilation and blood flow. The superior effect of BMOV on collateral blood flow over VEGF alone may reflect enhanced activation of Tie-2 or other angiogenic receptors including FGF, platelet-derived growth factor, and the insulin receptor. Indeed, previous studies in arterial insufficiency models indicated that VEGF and angiopoietin improved collateral blood flow beyond the effect of either growth factor alone, which suggests that optimal collateral development may require the activation of multiple angiogenic or vascular remodeling pathways (5, 41). Whichever pathways are affected, the results presented herein strongly suggest that PTP inhibition led to enhanced activation of endothelial RTKs and is the molecular mechanism underlying the beneficial effects of BMOV on collateral blood flow.

Although BMOV increased growth factor-induced RTK phosphorylation, endothelial cell survival, and angiogenic responses in vitro, PTP inhibition was also efficacious in the absence of exogenously added growth factors in vivo, which suggests that PTP inhibition may provide a clinical benefit by augmenting innate signaling cues for vascular remodeling in pathological states. A plausible stimulus for this effect may be mediated through amplification of inherent signaling mechanisms provided by changes in shear stress (16, 23, 48). Indeed, shear stress has been shown to be an important contributor in vascular remodeling as a source for ligand-independent activation of several RTKs including VEGFR-2, Tie-2, and the insulin receptor (21, 27). Furthermore, PTP inhibition and shear stress have been demonstrated to activate endothelial nitric oxide synthase in a calcium-independent manner (10), which would presumably promote vascular remodeling and collateral blood flow.

Although BMOV increased collateral blood flow in the hindlimb, we cannot at present distinguish whether this effect was due to angiogenesis (development of new collateral channels) or enlargement of existing collateral vessels (sometimes referred to as arteriogenesis). Previous studies have demonstrated that remodeling of preexisting collateral vessels occurs in this model, which suggests that collateral enlargement is the major contributor to blood flow improvements (18, 53). In addition, stimulation of angiogenesis (increased capillary density) in the rabbit hindlimb using adenoviral expression of VEGF165 did not improve hindlimb blood flow (17), which suggests enlargement of preexisting collaterals, not angiogenesis, is the most prominent factor to collateral blood flow. However, BMOV did enhance angiogenesis in the rat aortic ring model, thereby indicating that neovascularization cannot be excluded. In the present study, using fluorescent microspheres to measure collateral blood flow precluded measurements of anatomical changes in the hindlimb vasculature in response to phosphatase inhibition, but future studies will address this question.

PTPs implicated in regulation of endothelial signaling. PTPs play important roles in a number of biological systems including the nervous system, immune system, and hematopoietic system (28, 30). In addition, some PTPs, such as SHPTP-2, positively regulate growth factor receptor signaling (28, 59) and may perhaps provide an alternative explanation for inhibition of vessel growth in the rat aortic ring model at higher concentrations of BMOV. On the basis of these findings, it is likely that a selective PTP inhibitor will have advantages both in safety and efficacy. Thus it is important to identify the target PTPs that are responsible for the negative regulation of endothelial RTK signaling.

Although our study demonstrates the utility of PTP inhibition for the treatment of vascular disease, we cannot at present distinguish which PTPs may be involved in the beneficial effects of BMOV. However, a number of PTPs have recently been implicated in the regulation of endothelial RTK activation and are likely candidates. For example, we have shown that adenoviral-mediated overexpression of HCPTP-A, a PTP that is identified by its association with VEGFR-2, attenuated VEGFR-2 activation, endothelial cell proliferation and migration, and inhibited angiogenesis in the rat aortic ring assay (19). In another study, small-molecule inhibitors of PTP-1B were found to enhance VEGFR-2 activation in endothelial cells and to augment angiogenesis in a Matrigel plug assay (43). These findings are particularly relevant to the present study, because BMOV was recently shown to inhibit several of these PTPs including HCPTP-A, HPTP-{beta}, PTP-1B, and SHP-2 (36). Future studies will aim at deciphering the specific PTP(s) involved in modulating vascular remodeling.

Intriguingly, just as the VEGFR family and the Tie family of RTKs are expressed predominantly in endothelial cells and play important roles in vascular development, several receptor type PTPs (rPTPs) are also expressed in endothelial cells, but their roles in vascular development have not been fully clarified (2). HPTP-{beta} and HPTP-{eta}, two closely related rPTPs, are both expressed predominantly in endothelial cells and their expression increases with cell density, a finding that suggests a role for these receptors in growth control (3, 11). Consistent with this possibility, HPTP-{beta} was recently shown to interact with Tie-2 and negatively regulate its phosphorylation when cotransfected in COS-1 cells (9). Another receptor PTP, PTP-{epsilon}, is also expressed predominantly in endothelial cells, and retroviral overexpression in HUVECs negatively regulated survival and proliferation (45). Although these data suggest a role for receptor PTPs in regulation of endothelial signaling, clearly much work is needed to understand their functions during blood vessel assembly and remodeling.

Limitations to current approach. Although this study demonstrates the therapeutic potential of PTP inhibition, our data suggest that its usefulness may be limited. BMOV promoted angiogenesis in the aortic ring at low concentrations; however, vessel formation was inhibited with higher doses. Moreover, the positive effects of BMOV on endothelial cell survival were reversed at higher concentrations (>100 µmol/l; data not shown), which indicate that selective PTP inhibition is likely necessary to provide clinical benefit. In addition, those promoting proangiogenic therapy must be mindful of the balance between enhancing collateral remodeling and potentially augmenting pathological angiogenesis. Thus patients receiving any proangiogenic therapy should be screened for conditions such as diabetic retinopathy or cancer that could be accelerated by enhancing angiogenesis.

Potential advantages of PTP inhibition for proangiogenesis and therapeutic implications. It is well accepted that patients with a robust network of preexisting collateral blood vessels fair better in response to occlusive artery disease (38). Furthermore, the risk of death from cardiovascular events in patients with PVD are similar to patients with coronary artery or cerebrovascular disease (14), which emphasizes the importance of developing novel means of establishing collateral vessels in high-risk patients.

To this end, data presented in this study suggest that inhibiting PTPs to enhance RTK activation and collateral remodeling may offer advantages over current approaches using growth factors. First, PTP inhibition is amenable to the development of a small molecule (57) and does not depend on the delivery of peptides in vivo, which are more difficult to produce and deliver and can be degraded by endogenous peptidases (8). Identification of a selective small molecule seems plausible based on the limited number of PTPs that have been identified as regulators of endothelial RTKs and the recent data that indicate success in generating specific small-molecule inhibitors of PTP-1B (58). Second, inhibition of PTPs could circumvent the need for administering multiple growth factors, providing that a single phosphatase can be identified that regulates multiple receptors. The ability of BMOV to enhance blood flow in vivo in the absence of exogenously added growth factors suggests that PTP inhibition may not require a combinatory approach, although this possibility requires further investigation. Finally, decreasing PTP activity could allow for more control of the vascular remodeling process because PTP inhibitors would amplify the body's physiological response to ischemia. This may be critical to successful proangiogenic therapy, because administration of large amounts of exogenous VEGF can lead to untoward side effects including vascular leakage, edema, inflammation, and even angioma formation (29, 40, 46). Likewise, deciphering the precise roles of phosphatase(s) involved in the improvement of collateral blood flow observed in this study is critical in separating the beneficial and adverse consequences of PTP inhibition. In any case, our findings indicate that PTPs regulate endothelial RTK activation and validate PTP inhibition as a novel approach for proangiogenic therapy of occlusive cardiovascular disease.


   ACKNOWLEDGMENTS
 
The authors gratefully acknowledge Lin Fei for critical statistical review and Paula Loos for expert technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: A. N. Carr, Procter and Gamble Pharmaceuticals, 8700 Mason Montgomery Rd., Box 1064, Mason, OH 45040 (E-mail: carr.an{at}pg.com).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR III, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, and Weber MA. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163: 884–892, 2003.[Free Full Text]
  2. Bianchi C, Sellke FW, Del Vecchio RL, Tonks NK, and Neel BG. Receptor-type protein-tyrosine phosphatase mu is expressed in specific vascular endothelial beds in vivo. Exp Cell Res 248: 329–338, 1999.[CrossRef][Web of Science][Medline]
  3. Borges LG, Seifert RA, Grant FJ, Hart CE, Disteche CM, Edelhoff S, Solca FF, Lieberman MA, Lindner V, Fischer EH, Lok S, and Bowen-Pope DF. Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells. Circ Res 79: 570–580, 1996.[Abstract/Free Full Text]
  4. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, and Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604–613, 2003.[CrossRef][Web of Science][Medline]
  5. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, and Koh GY. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20: 2573–2578, 2000.[Abstract/Free Full Text]
  6. Conway EM, Collen D, and Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507–521, 2001.[Free Full Text]
  7. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, and Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283: 1544–1548, 1999.[Abstract/Free Full Text]
  8. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, and Zioncheck TF. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72: 20–32, 2002.[CrossRef][Web of Science][Medline]
  9. Fachinger G, Deutsch U, and Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 18: 5948–5953, 1999.[CrossRef][Web of Science][Medline]
  10. Fleming I, Bauersachs J, Fisslthaler B, and Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 82: 686–695, 1998.[Abstract/Free Full Text]
  11. Gaits F, Li RY, Ragab A, Ragab-Thomas JM, and Chap H. Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells. Biochem J 311: 97–103, 1995.[Web of Science][Medline]
  12. Gale NW and Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13: 1055–1066, 1999.[Free Full Text]
  13. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, and Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336–30343, 1998.[Abstract/Free Full Text]
  14. Halperin JL and Fuster V. Meeting the challenge of peripheral arterial disease. Arch Intern Med 163: 877–878, 2003.[Free Full Text]
  15. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, and Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol Heart Circ Physiol 270: H1791–H1802, 1996.[Abstract/Free Full Text]
  16. Helisch A and Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 10: 83–97, 2003.[CrossRef][Web of Science][Medline]
  17. Hershey JC, Baskin EP, Corcoran HA, Bett A, Dougherty NM, Gilberto DB, Mao X, Thomas KA, and Cook JJ. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels 18: 142–149, 2003.[CrossRef][Web of Science][Medline]
  18. Herzog S, Sager H, Khmelevski E, Deylig A, and Ito WD. Collateral arteries grow from preexisting anastomoses in the rat hindlimb. Am J Physiol Heart Circ Physiol 283: H2012–H2020, 2002.[Abstract/Free Full Text]
  19. Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, and Peters KG. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem 274: 38183–38188, 1999.[Abstract/Free Full Text]
  20. Hunter T. Signaling—2000 and beyond. Cell 100: 113–127, 2000.[CrossRef][Web of Science][Medline]
  21. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, and Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 93: 354–363, 2003.[Abstract/Free Full Text]
  22. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, and Dumont DJ. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274: 30896–30905, 1999.[Abstract/Free Full Text]
  23. Kersten JR, Pagel PS, Chilian WM, and Warltier DC. Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia. Cardiovasc Res 43: 44–57, 1999.[Abstract/Free Full Text]
  24. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, and Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res 86: 24–29, 2000.[Abstract/Free Full Text]
  25. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, and Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20: 5479–5489, 2000.[Abstract/Free Full Text]
  26. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, and Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94: 1074–1082, 1996.[Abstract/Free Full Text]
  27. Lee HJ and Koh GY. Shear stress activates Tie2 receptor tyrosine kinase in human endothelial cells. Biochem Biophys Res Commun 304: 399–404, 2003.[CrossRef][Web of Science][Medline]
  28. Li L and Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin Immunol 12: 75–84, 2000.[CrossRef][Web of Science][Medline]
  29. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M, Sugimachi K, and Sueishi K. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90: 966–973, 2002.[Abstract/Free Full Text]
  30. Neel BG and Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 9: 193–204, 1997.[CrossRef][Web of Science][Medline]
  31. Nicosia RF, Nicosia SV, and Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 145: 1023–1029, 1994.[Abstract]
  32. Nicosia RF and Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63: 115–122, 1990.[Web of Science][Medline]
  33. Ostman A and Bohmer FD. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol 11: 258–266, 2001.[CrossRef][Web of Science][Medline]
  34. Ouriel K. Peripheral arterial disease. Lancet 358: 1257–1264, 2001.[CrossRef][Web of Science][Medline]
  35. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, and Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102–9105, 2000.[Abstract/Free Full Text]
  36. Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, and Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem 96: 321–330, 2003.[CrossRef][Web of Science][Medline]
  37. Richardson TP, Peters MC, Ennett AB, and Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 19: 1029–1034, 2001.[CrossRef][Web of Science][Medline]
  38. Rogers WJ, Hood WP Jr, Mantle JA, Baxley WA, Kirklin JK, Zorn GL, and Nath HP. Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenoses or intact collaterals. Circulation 69: 338–349, 1984.[Abstract/Free Full Text]
  39. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103: 211–225, 2000.[CrossRef][Web of Science][Medline]
  40. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, and Kloner RA. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat—angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323–1330, 2000.[Abstract/Free Full Text]
  41. Shyu KG, Chang H, and Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 73: 563–579, 2003.[CrossRef][Web of Science][Medline]
  42. Shyu KG, Manor O, Magner M, Yancopoulos GD, and Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98: 2081–2087, 1998.[Abstract/Free Full Text]
  43. Soeda S, Shimada T, Koyanagi S, Yokomatsu T, Murano T, Shibuya S, and Shimeno H. An attempt to promote neo-vascularization by employing a newly synthesized inhibitor of protein tyrosine phosphatase. FEBS Lett 524: 54–58, 2002.[CrossRef][Web of Science][Medline]
  44. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, and Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662–670, 1994.[Web of Science][Medline]
  45. Thompson LJ, Jiang J, Madamanchi N, Runge MS, and Patterson C. PTP-{epsilon}, a tyrosine phosphatase expressed in endothelium, negatively regulates endothelial cell proliferation. Am J Physiol Heart Circ Physiol 281: H396–H403, 2001.[Abstract/Free Full Text]
  46. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, and Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460–463, 2000.[CrossRef][Web of Science][Medline]
  47. Tsiani E and Fantus IG. Vanadium compounds: biological actions and potential as pharmacological agents. Trends Endocrinol Metab 8: 51–58, 1997.[Medline]
  48. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 38: 198–203, 2003.[CrossRef][Web of Science][Medline]
  49. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR, Heinsohn HG, Ferrara N, and Thomas GR. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 27: 91–98, 1996.[CrossRef][Web of Science][Medline]
  50. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, and Taylor LM. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94: 3026–3049, 1996.[Free Full Text]
  51. Whitaker GB, Limberg BJ, and Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121. J Biol Chem 276: 25520–25531, 2001.[Abstract/Free Full Text]
  52. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, and Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81: 567–574, 1997.[Abstract/Free Full Text]
  53. Yang HT, Deschenes MR, Ogilvie RW, and Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res 79: 62–69, 1996.[Abstract/Free Full Text]
  54. Yang HT, Laughlin MH, and Terjung RL. Prior exercise training increases collateral-dependent blood flow in rats after acute femoral artery occlusion. Am J Physiol Heart Circ Physiol 279: H1890–H1897, 2000.[Abstract/Free Full Text]
  55. Yang HT, Ren J, Li H, and Terjung RL. Angiopoietin-1 increases collateral dependent blood flow in rats with bilateral artery ligation (Abstract). FASEB J 15: A118, 2001.
  56. Yang HT, Yan Z, Abraham JA, and Terjung RL. VEGF121- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol 280: H1097–H1104, 2001.[Abstract/Free Full Text]
  57. Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. Curr Opin Chem Biol 5: 416–423, 2001.[CrossRef][Web of Science][Medline]
  58. Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol 42: 209–234, 2002.[CrossRef][Web of Science][Medline]
  59. Zhao Z, Tan Z, Wright JH, Diltz CD, Shen SH, Krebs EG, and Fischer EH. Altered expression of protein-tyrosine phosphatase 2C in 293 cells affects protein tyrosine phosphorylation and mitogen-activated protein kinase activation. J Biol Chem 270: 11765–11769, 1995.[Abstract/Free Full Text]
  60. Zhu WH, MacIntyre A, and Nicosia RF. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am J Pathol 161: 823–830, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. N. Carr, B. W. Howard, H. T. Yang, E. Eby-Wilkens, P. Loos, A. Varbanov, A. Qu, J. P. DeMuth, M. G. Davis, A. Proia, et al.
Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism
Cardiovasc Res, March 1, 2006; 69(4): 925 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Duerschmied, L. Olson, M. Olschewski, A. Rossknecht, G. Freund, C. Bode, and C. Hehrlein
Contrast ultrasound perfusion imaging of lower extremities in peripheral arterial disease: a novel diagnostic method
Eur. Heart J., February 1, 2006; 27(3): 310 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K. Kappert, K. G. Peters, F. D. Bohmer, and A. Ostman
Tyrosine phosphatases in vessel wall signaling
Cardiovasc Res, February 15, 2005; 65(3): 587 - 598.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/H268    most recent
00007.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, A. N.
Right arrow Articles by Peters, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, A. N.
Right arrow Articles by Peters, K. G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.